AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Revenue Boom: Total revenue surged 32.15% to $100.79 million, driven by North American performance.
- Profit Growth: Net profit soared 42.7% to a record $51.7 million.
- Dividend Increase: Fully franked interim dividend up 38.9% to 25 cents per share.
Shares of Pro Medicus Limited (ASX:PME) traded 4.74% lower at $274.64 on Thursday following the release of its half-year results. The health imaging technology leader posted positive revenue and profit growth, reinforcing its dominant position in the medical imaging sector.
For the six months ending 31 December 2024, Pro Medicus achieved total revenue growth of 32.15% to $100.79 million, with revenue from ordinary activities climbing 31.1% to $97.2 million. The impressive performance was primarily driven by its North American segment, which saw revenue rise 34.6% to $86.4 million following the completion of major contract implementations.
The company also saw modest growth in Europe (0.8%) and Australia (10.8%), with the latter benefitting from the renewal of a five-year contract extension with a large Australian Radiology Network.
Profitability Strengthens as Margins Expand
Pro Medicus’ EBIT margin expanded from 66% to 72%, reflecting improved operational efficiency and revenue growth. This translated into a 42.9% surge in underlying profit before tax to $69.9 million and a 42.7% increase in net profit to a record $51.7 million.
Earnings per share (EPS) also jumped 42.7% to 49.53 cents, surpassing market expectations of 47.7 cents per share.
The company’s robust financial position, with $182.3 million in cash and no debt, enabled a 38.9% increase in its interim dividend to 25 cents per share—beating analysts’ expectations of 24.2 cents per share.
Growth Outlook: Expanding Global Footprint
Looking ahead, Pro Medicus is actively pursuing further expansion in North America, Germany, and Australia, targeting academic hospitals, integrated delivery networks, and private imaging centers.
With a growing number of contract opportunities and continued margin expansion, the company remains well-positioned for sustained growth.
